# Pharmaceutical Industry: Resources

This section provides a curated list of key research, government reports, investigative journalism, legal resources, and data sources on the pharmaceutical industry, drug pricing, FDA regulation, and pharmaceutical accountability.

---

## Academic Research

### Peer-Reviewed Studies

- Galkina Cleary, E., Beiber, L., Tubbs, D., et al. "Contribution of NIH Funding to New Drug Approvals 2010-2016." *PNAS* 115.10 (2018): 2329-2334. <https://doi.org/10.1073/pnas.1715368115>
- Downing, N.S., Shah, N.D., Aminawung, J.A., et al. "Postmarket Safety Events Among Novel Therapeutics Approved by the US FDA As Accelerated Approvals vs Conventional Approvals." *JAMA Internal Medicine* 177.8 (2017): 1122-1129.
- DeJong, C., Aguilar, T., Tseng, C., et al. "Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries." *JAMA Internal Medicine* 176.8 (2016): 1114-1122.
- DiMasi, J.A., Grabowski, H.G., Hansen, R.W. "Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs." *Journal of Health Economics* 47 (2016): 20-33.
- Woloshin, S., Schwartz, L.M., White, B., Moore, T.J. "The Fate of FDA Postapproval Studies." *New England Journal of Medicine* 377 (2017): 1114-1117.
- Schwartz, L.M., Woloshin, S. "Medical Marketing in the United States, 1997-2016." *JAMA* 321.1 (2019): 80-96.
- Bourgeois, F.T., Murthy, S., Mandl, K.D. "Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov." *Annals of Internal Medicine* 153.3 (2010): 158-166.
- McCoy, M.S., Carniol, M., Chockley, K., et al. "Conflicts of Interest for Patient-Advocacy Organizations." *New England Journal of Medicine* 376 (2017): 880-885.
- Topol, E.J. "Failing the Public Health -- Rofecoxib, Merck, and the FDA." *New England Journal of Medicine* 351.17 (2004): 1707-1709.

### Working Papers and White Papers

- Mulcahy, A.W., Schwam, D., Edenfield, N. "Comparing Prescription Drug Prices in the United States to Other Countries." RAND Corporation Research Report RR-2956-ASPEC. 2021. <https://www.rand.org/pubs/research_reports/RR2956.html>
- I-MAK. "Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Is Extending Monopolies and Driving Up Drug Prices." 2023. <https://www.i-mak.org/overpatented-overpriced/>
- Sarpatwari, A., DiBello, J., Gagne, J.J., Kesselheim, A.S. "Pay-for-Delay Agreements: Updated Review of the Literature." Working Paper. Harvard Program on Regulation, Therapeutics, and Law. 2022.

---

## Government Reports and Data

### Federal Agencies

- Congressional Budget Office. "Estimated Budgetary Effects of Public Law 117-169, the Inflation Reduction Act of 2022." September 2022. <https://www.cbo.gov/publication/58455>
- House Committee on Oversight and Reform. "Drug Pricing Investigation: Industry Spending on Buybacks, Dividends, and Executive Compensation." Staff Report. July 2021. <https://oversightdemocrats.house.gov/legislation/reports>
- Federal Trade Commission. "Interim Report on Pharmacy Benefit Managers." July 2024. <https://www.ftc.gov/reports/pharmacy-benefit-managers-report>
- Government Accountability Office. "Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals." GAO-18-40. November 2017. <https://www.gao.gov/products/gao-18-40>
- House Committee on Energy and Commerce. "Investigation of the FDA's Accelerated Approval of Aduhelm." Staff Report. 2022.

### Congressional Reports

- Congressional Research Service. "Prescription Drug Pricing in the United States: Overview of the Law and Legislative Actions." Report R47243. 2023.
- Congressional Research Service. "Pharmacy Benefit Managers and the Prescription Drug Supply Chain." Report R46551. 2024.
- Congressional Research Service. "The Inflation Reduction Act's Prescription Drug Provisions." Report IN11980. 2023.

### Agency Data Portals

- FDA. Drugs@FDA Database. <https://www.accessdata.fda.gov/scripts/cder/daf/> - Approval history, labeling, and safety information for all approved drugs
- CMS. Medicare Drug Spending Dashboard. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/> - Part B and Part D drug spending data
- CMS. Open Payments (Sunshine Act). <https://openpaymentsdata.cms.gov/> - Industry payments to physicians and teaching hospitals
- FDA. Drug Shortages Database. <https://www.accessdata.fda.gov/scripts/drugshortages/> - Current and resolved drug shortages

---

## Books

- Keefe, Patrick Radden. *Empire of Pain: The Secret History of the Sackler Dynasty*. Doubleday, 2021. - Definitive account of the Sackler family and Purdue Pharma's role in the opioid crisis
- Posner, Gerald. *Pharma: Greed, Lies, and the Poisoning of America*. Avid Reader Press, 2020. - History of the pharmaceutical industry from its origins to modern controversies
- Macy, Beth. *Dopesick: Dealers, Doctors, and the Drug Company That Addicted America*. Little, Brown and Company, 2018. - Ground-level reporting on the opioid crisis and Purdue Pharma's role
- Angell, Marcia. *The Truth About the Drug Companies: How They Deceive Us and What to Do About It*. Random House, 2005. - Former *NEJM* editor's critique of industry practices
- Goldacre, Ben. *Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients*. Faber & Faber, 2012. - Analysis of clinical trial bias, marketing practices, and regulatory capture
- Sackler, Nan Goldin, et al. *All the Beauty and the Bloodshed*. Film documentary. 2022. - Documentary on the Sackler family and opioid accountability activism

---

## Think Tank Analysis

### Research Organizations

- RAND Corporation. "International Prescription Drug Price Comparisons." Multiple reports, 2019-2024. <https://www.rand.org/topics/prescription-drug-costs.html> - Comprehensive U.S.-international price comparison data
- Brookings Institution. "A Dozen Facts About the Economics of the U.S. Health-Care System." 2020. <https://www.brookings.edu/research/>
- Commonwealth Fund. "Prescription Drug Costs in Context." 2023. <https://www.commonwealthfund.org/> - Comparative health system analysis including drug pricing
- Kaiser Family Foundation. Health Tracking Polls on Prescription Drug Costs. Multiple years. <https://www.kff.org/> - Public opinion and affordability data

### Policy Briefs

- Center for American Progress. "Confronting Pharmaceutical Industry Consolidation and Abuse." 2023. <https://www.americanprogress.org/>
- American Enterprise Institute. "Drug Pricing: What Do We Know?" 2023. <https://www.aei.org/>
- Niskanen Center. "Patent Reform for Pharmaceutical Innovation." 2022. <https://www.niskanencenter.org/>

---

## Organizations and Advocacy Groups

| Organization | Focus | Type | Website |
|--------------|-------|------|---------|
| Patients for Affordable Drugs NOW | Drug pricing reform advocacy | Advocacy | <https://www.patientsforaffordabledrugs.org/> |
| AARP | Drug pricing, Medicare benefits | Advocacy | <https://www.aarp.org/> |
| Public Citizen | FDA reform, drug safety, corporate accountability | Advocacy / Research | <https://www.citizen.org/> |
| Knowledge Ecology International (KEI) | Patent policy, access to medicines | Research / Advocacy | <https://www.keionline.org/> |
| I-MAK (Initiative for Medicines, Access & Knowledge) | Patent system reform | Research / Advocacy | <https://www.i-mak.org/> |
| National Academy for State Health Policy (NASHP) | State-level drug pricing policy | Research | <https://www.nashp.org/> |
| Drug Channels Institute | Pharmaceutical supply chain analysis | Research | <https://drugchannelsinstitute.com/> |
| Civica Rx | Nonprofit generic drug manufacturing | Nonprofit manufacturer | <https://www.civicainc.org/> |
| Cost Plus Drug Company | Transparent drug pricing | Pharmacy | <https://costplusdrugs.com/> |

---

## Data Sources

| Dataset | Provider | Update Frequency | URL | Description |
|---------|----------|------------------|-----|-------------|
| IQVIA National Sales Perspectives | IQVIA | Monthly | <https://www.iqvia.com/> | U.S. pharmaceutical sales data by product and channel |
| OECD Health Statistics | OECD | Annual | <https://stats.oecd.org/> | International health spending comparisons including pharmaceuticals |
| National Health Expenditure Data | CMS | Annual | <https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data> | U.S. healthcare spending by category |
| FDA Orange Book | FDA | Continuous | <https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book> | Patent and exclusivity listings for approved drugs |
| Open Payments | CMS | Annual | <https://openpaymentsdata.cms.gov/> | Industry payments to physicians |
| OpenSecrets Lobbying Data | OpenSecrets | Quarterly | <https://www.opensecrets.org/> | Lobbying expenditures and campaign contributions by industry |
| GoodRx Drug Pricing Research | GoodRx | Monthly/Quarterly | <https://www.goodrx.com/healthcare-access/drug-cost-and-savings> | Retail drug price trends and analysis |

---

## News and Journalism

### Investigative Reports

- STAT News. Ongoing pharmaceutical industry and FDA coverage. <https://www.statnews.com/> - Premier source for pharmaceutical industry reporting
- New York Times. "The Family That Built an Empire of Pain." Patrick Radden Keefe. October 2017. <https://www.newyorker.com/> - Foundational Sackler family investigation
- ProPublica. "Dollars for Docs." <https://projects.propublica.org/docdollars/> - Interactive database of industry payments to physicians
- Reuters. "The Opioid Files." 2019-2024. <https://www.reuters.com/investigates/> - Ongoing investigation into opioid industry practices
- Washington Post. "The Opioid Files." 2019-2024. <https://www.washingtonpost.com/graphics/investigations/dea-pain-pill-database/> - Analysis of DEA pharmaceutical distribution data

### Ongoing Coverage

- *STAT News*. Daily pharmaceutical industry coverage. <https://www.statnews.com/> - Industry's most-read news source; covers FDA, drug pricing, biotech, clinical trials
- *Kaiser Health News (KHN)*. "Bill of the Month" series. <https://khn.org/news/tag/bill-of-the-month/> - Patient stories of medical billing including drug costs

---

## International Sources

- OECD. "Health at a Glance: OECD Indicators." Annual. <https://www.oecd.org/els/health-systems/health-at-a-glance.htm>
- World Health Organization. "WHO Essential Medicines List." Updated biennially. <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines>
- National Institute for Health and Care Excellence (NICE). Technology Appraisal Guidance. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance>
- Patented Medicine Prices Review Board (Canada). Annual Reports. <https://www.canada.ca/en/patented-medicine-prices-review.html>

---

## Legal Resources

### Case Law

- *FTC v. Actavis, Inc.*, 570 U.S. 136 (2013). - Supreme Court held that "pay-for-delay" settlements can violate antitrust law
- *Harrington v. Purdue Pharma L.P.*, 603 U.S. ___ (2024). - Supreme Court addressed nonconsensual third-party releases in Purdue bankruptcy
- *New York v. Actavis PLC*, 787 F.3d 638 (2d Cir. 2015). - "Product hopping" can constitute anticompetitive conduct
- *Sorrell v. IMS Health Inc.*, 564 U.S. 552 (2011). - First Amendment limits on pharmaceutical data mining restrictions

### Statutory References

- 21 U.S.C. 301 et seq. - Federal Food, Drug, and Cosmetic Act (FDA authority)
- 35 U.S.C. 101-376 - Patent Act (intellectual property framework)
- 42 U.S.C. 1395w-111 et seq. - Medicare Part D (prescription drug benefit)
- Public Law 117-169 (Inflation Reduction Act of 2022) - Medicare drug negotiation authority

---

## Document Navigation

- Up: [Drugs Overview](../01-overview.md)
- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
